The Dotmatics Enterprise Platform is Licensed by Redx Pharma
News Jan 31, 2013
Dotmatics Limited announced that Redx Pharma have licensed and deployed Dotmatics’ entire suite of scientific informatics solutions. This deployment delivers an integrated system that improves access to data, allows the sharing of information and promotes collaboration across different research groups at Redx. Redx develops new drug candidates across eleven different therapeutic classes using its Redox SwitchTM Platform. The company is undergoing a process of rapid expansion. This constant growth creates a dynamic research environment that requires an informatics platform able to hold increasing amounts of complex and diverse data. In addition, it has to be easy to use and intuitive in order to facilitate the quick and efficient adoption by users. Furthermore, the system has to prevent input errors and it has to be compliant with directives from regulatory authorities.
After extensive testing, the Dotmatics Platform proved to be the most flexible informatics system capable of integrating diverse discovery activities from chemistry to biology. The Dotmatics Platform provides Redx with comprehensive informatics solutions to successfully store, query, manage, visualise and analyse their two hundred families of compounds and all associated data.
Using Studies Notebook, chemists and biologists at Redx easily and securely store their structured and unstructured data in a single web-based system. Scientists are able to access their data faster, aggregate them in a single interface and create custom reports in a productive and efficient manner using Browser. Browser is a scalable and robust query and visualisation tool for biological and chemical datasets alike. Dotmatics’ flagship solution Vortex is a world-class visualisation and analytics platform designed specifically to work with scientific data. Vortex provides scientists at Redx with an out-of the-box filtering, charting, plotting and chemically aware calculations engine, enabling scientists to evaluate large datasets in a rich, intuitive and flexible user interface.
Dotmatics CEO, Stephen Gallagher, PhD, said “We are delighted to be working with such a forward thinking organisation as Redx Pharma and we are looking forward to further collaboration with them as both companies continue to develop and move forward.”
Dr Neil Murray, CEO of Redx Pharma, said: “Redx is a rapidly growing drug discovery and development company that was looking to install a single informatics platform solution that could address our needs as we grow. “We chose Dotmatics as we felt they provided the best balance of flexibility against range of capability.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: RNA Sequencing Library Preparation - How Low Can You Go?
Mar 19 - Mar 23, 2018
EMBL Course: Analysis and Integration of Transcriptome and Proteome Data
Mar 12 - Mar 16, 2018